IMMUNE is focused on developing the next generation of monoclonal antibodies to address significant unmet medical needs in the treatment of cancer and inflammatory diseases. Our goal is to improve patients' lives through targeted medicine.
IMMUNE Pharmaceuticals is an Israeli-based emerging leader in the development of Monoclonal Antibodies for the treatment of Inflammatory Diseases and Cancer. Monoclonal Antibodies are one of the most attractive pharmaceutical markets with annual sales of over $50 billion, continued double digit growth, 5 out of the top 10 pharmaceuticals, high market valuation and rich partnerships, including for earlier development stage drugs.
IMMUNE is in-licensing clinical stage first in class monoclonal antibodies. Our lead program, Bertilimumab. is ready for phase II in Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis) and Severe Asthma. Bertilimumab was originally developed by CAT (now part of MedImmune, the biologics division of AstraZeneca) and licensed to iCo Therapeutics (TSX:ICO) which retains the rights for ophthalmology.
IMMUNE Discovery Platform is focused on improving the efficacy of first generation monoclonal antibodies. The lead technology is NanomAbs, conjugates of Monoclonal Antibodies and drug-loaded Nanoparticles, was developed by Professor Benita at Hebrew University. It is an alternative to the Antibody Drug Conjugate technology. IMMUNE is establishing revenue generating early partnerships with leading biotech and pharmaceutical companies to help them build a stronger biologics pipeline.
IMMUNE Management Team and Scientific Advisors are delivering on their vision to create a world class portfolio, with multiple shots on goal for $1+ billion drugs. IMMUNE is ready to execute development plans and corporate partnerships to maximize shareholder value.